ABSTRACT. Because of their unsurpassed potency in presenting antigens to naive T cells, dendritic cells are considered to be an important candidate in the development of immunotherapeutic strategies. Despite the high potential of dendritic cell-based immunotherapy, as a so-called dendritic cell vaccination, few clinical approaches using dendritic cell vaccination have been performed in the dog because of very limited information regarding the generation of canine dendritic cells and their functional properties. We therefore established a protocol for the efficient generation of dendritic cells from canine bone marrow cells using recombinant feline granulocyte-macrophage colony-stimulating factor and canine interleukin-4. Dendritic cells were generated efficiently: a yield of 1-9 × 10 6 cells per approximately 0.5 ml of canine bone marrow aspiration was achieved. These dendritic cells showed features shared with mouse and human dendritic cells: dendrite morphology, expression of surface markers MHC class II and CD11c, and up-regulation of molecules related to antigen presentation (MHC class II, B7-1, and B7-2) by activation with lipopolysaccharide. Moreover, the dendritic cells demonstrated phagocytic activity, processing activity of pinocytosed proteins, and activation of allogeneic T cells far more potent than that by macrophages. Our findings suggest that the bone marrow-derived dendritic cells are functional for the capturing and processing of antigens and the initiation of T cell responses.
Dendritic cells (DC) are critical to immunity because of their unsurpassed potency in presenting antigens to naive T cells for the generation of primary cellular and humoral immune responses against viral, microbial, and even tumorassociated antigens [2, 18] . This superior immunostimulatory capacity of DC renders them the most important candidate in the development of immunotherapeutic strategies against malignant tumors as well as infectious pathogens. In fact, one strategy, the so-called DC vaccination, in which DC were loaded with tumor-derived solubilyzed protein or tumor-associated antigen and injected back into the body to initiate T cell responses, has been shown to elicit tumor-specific T cells, resulting in anti-tumor activities in mouse models [1, 14, 26] and tumor regression in human clinical cases [5, 19, 21] . However, few clinical approaches using the DC vaccination for tumor treatment have been performed in the dog because of very limited information regarding the generation of canine DC and their functional properties.
Human DC may now be generated in vitro from peripheral blood CD34
+ precursor cells [6, 20] or monocytes [15, 17, 27] in the presence of cytokines such as granulocytemacrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), tumor necrosis factor-α (TNF-α), Flt3 ligand, and CD 40 ligand, and their function is well characterized. The vast majority of current clinical trials of DC vaccination for patients with tumors use monocyte-derived DC rather than CD34 + cells because of the latter's complicated procedure and huge volume of blood required for purification; however, even the generation of DC from monocytes requires a large volume of peripheral blood (usually 100 ml to 200 ml) [5, 19] or leukophoresis [11, 21] . With respect to canines, the low volume of circulating blood compare to that in humans made it difficult to generate a sufficient number of functional monocyte-derived DC from peripheral blood for vaccination against malignant tumors.
In contrast to that from humans, a large amount of DC can be generated in vitro from mouse bone marrow cells in the presence of GM-CSF and IL-4 or with other additive cytokines such as TNF-α and Flt3 ligand, and these DC have been shown to induce anti-tumor immunity (by the induction of tumor-specific CD8 T cells), resulting in the elimination of tumors such as chemical-induced sarcoma, fibrosarcoma, acute myelo-leukemia, melanoma, and squamous cell carcinoma in vivo [1, 12, 14, 24] . Encouraged by the successful applications of the DC vaccination to mouse cancer models, we attempted to generate DC from canine bone marrow cells and characterize their properties.
MATERIALS AND METHODS

Animals and bone marrow aspirations:
Beagles (2-3 years old) were housed and cared for in the facility of the Institutional Life Care Use Center at Nippon Veterinary and Life Science University, and all the experiments were conducted in accordance with the guidelines of the university. After the dogs were anesthetized with medetomidine, an approximate total volume of 0.5 ml bone marrow from the femur and ileum was obtained by aspiration with a syringe containing 2 ml of 16 mM EDTA-2Na/phosphate-buffered saline. Macrophages were also collected from the alveoli of the dogs by bronchoalveolar lavage.
Cell culture: Mononuclear cells were isolated from bone marrow aspirations by density gradient centrifugation using Histopaque-1077 (Sigma-Aldrich, St. Louis, MO) spun at 500 × g at 22°C for 30 min. After washing with phosphatebuffered saline, the cells were suspended in RPMI-1640 culture medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% fetal calf serum (Nippon Bio-supply Center, Tokyo, Japan) and 1% penicillin-streptomycinglutamine (Invitrogen, Carlsbad, CA), and cultured in 6-well plates (2 × 10 6 cells/well) at 37°C in a humidified 5% CO 2 -containing atmosphere. The recombinant feline GM-CSF (R&D Systems, Minneapolis, MN) and canine IL-4 (R&D Systems) were added to the culture medium at doses of 20 ng/ml each. On Days 3 and 5 of culture, 80% of the medium volume (1.6 ml) was changed, removing nonadherent cells but allowing loosely adherent cells to remain. On Day 7 of culture, loosely adherent cells were harvested and cultured for an additional 3 days. In some experiments, lipopolysaccharide (E. coli 0127: B8, Sigma-Aldrich) was added into the medium on Day 7 of culture at a concentration of 250 ng/ml. On Day 10 of culture, aliquot of cells were subjected to cytospin and stained with Wright-Giemsa solution.
Transmission electron microscopy: Bone marrow cells cultured for 10 days were washed with 0.1 M phosphate buffer (pH 7.4) and centrifuged at 200 × g for 5 min at 4°C to form pellets. The pellets were soaked in Karnovsky's fixative solution (pH 7.2) for 30 min at 4°C. The cell pellets were then fixed with 1% osmium tetrachloride/phosphate buffer for 1 hr at 4°C, followed by three washings with phosphate buffer. Pellets were embedded in 1% agarose, followed by epoxy resin. Ultrathin sections of the pellets were stained with acetate uranium and lead citrate, and observed under a JEM100CX-II electron microscope (Jeol, Tokyo, Japan) at 80 kV.
Analysis of surface molecules: Cells were stained with fluorescein isothiocyanate (FITC)-conjugated rat anticanine major histocompatibility complex (MHC) class II (Serotec, Oxford, UK), mouse anti-canine CD11c (Serotec), or each isotype control. For staining of CD11c, a second antibody, FITC-conjugated goat anti-mouse IgG (Cappel, Aurora, OH), was used. After staining with antibodies, cells were analyzed by a flow cytometer (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ).
Phagocytic and pinocytic processing ability: For examination of phagocytosis, cells (7.5 × 10 4 ) cultured for 10 days were incubated with 3.8 × 10 5 of fluorescence-labeled latex beads (Fluoresbrite YG Microspheres; Polyscience, Warrington, UK). Following incubation for 24 hr, cells were observed under a fluorescent microscope.
The cells' ability to process pinocytosed soluble protein was evaluated using DQ-ovalbumin (Molecular Probes, Eugene, OR) [22] , a self-quenching fluorescence-labeled ovalbumin. Cells (1 × 10 5 ) cultured for 10 days were incubated with DQ-ovalbumin (2 µg/ml) in medium for 1 hr at 37°C or on ice. The expression of fluorescence induced by the digestion of DQ-ovalbumin was detected by a flow cytometer.
Allogenic mixed lymphocyte reaction: To enrich T cells from the blood, peripheral blood mononuclear cells were isolated by density gradient centrifugation with Histopaque-1077 and cultured for 2 hr in medium. The nonadherent cells (mainly T cells) were separated from the adherent cells (mainly B cells and monocytes) by aspiration of the culture supernatant. The purity of T cells (typically more than 90%) was confirmed by flow cytometric analysis using anticanine CD3 antibody (Serotec). Enriched allogeneic T cells (1 × 10 5 cells) were cultured in medium for 4 days at 37°C with graded numbers (between 1 × 10 3 and 1 × 10 5 ) of stimulator cells (bone marrow cells cultured for 10 days or alveolar macrophages) in 96-well plates. The same numbers of stimulator cells were also cultured without T cells under the same conditions. The proliferation of allogeneic T cells was measured by BrdU incorporation using a commercial kit (Cell Proliferation Biotrak ELISA System version 2; Amersham Biosciences, Buckinghamshire, England). Briefly, BrdU was added to the cell culture, at a final concentration of 10 µM, 24 hr before cell fixation. The cells were fixed with ethanol and incubated with peroxidase-labeled antiBrdU antibody for 90 min. After removal of the antibody by three washes with phosphate-buffered saline, 100 µl of tetramethyl benzidine was added to the wells and the mixtures were incubated until color developed (15 min). Absorbance values were measured at 450 nm, and reference values were measured at 690 nm using an ELISA reader (Spectra Rainbow Thermo; Tecan AG, Hombrechtikon, Switzerland). Values of stimulator cultured without T cells were subtracted from values of mixed lymphocyte reaction samples to normalize incorporation of BrdU.
Detection of mRNA: Total RNA was extracted from cells cultured for 10 days, using an RNA-STAT 60 (Tel-TestB, Friendswood, TX) as described previously [3] . The RNA was reverse-transcribed into cDNA using SuperScript II reverse transcriptase (Invitrogen). An aliquot of cDNA was subjected to amplification by the polymerase chain reaction (PCR) using the following primer sets: canine B7-1, 5'-CTATTGGCAAAAGGATGATGAAG-3' and 5'-GTGTG-GCTCGACTGATTTTTG-3', B7-2, 5'-GGGCCCAAAG-GACTCGTT-3' and 5'-GGCCAGGCTGCTTCTTCTT-3', and β-actin, 5'-CTGGCCGGGACCTGACTGACTACC-3' and 5'-GCGTTCCGGAGGGGCGATGAT-3'. After PCR amplification for 25 cycles, an aliquot of amplification products was size-fractionated on a 1.0% agarose gel and the resulting bands were visualized by staining with ethidium bromide.
RESULTS
Generation of dendritic cells from bone marrow cells:
To generate DC, we cultured bone marrow cells in the presence of recombinant feline GM-CSF and canine IL-4. After 3 days of culture, the bone marrow cells formed loosely adherent clusters; cells that possessed dendritic projections were generated by further culturing these cell clusters (Fig.  1A) . During the 7 additional days of culture and two medium replacements, contaminated leukocytes such as neutrophils and lymphocytes were almost removed from the culture medium. Although some neutrophils still remained in the culture medium (approximately 5-10% of total cells under the microscope), the majority of the cultured cells became morphologically homogeneous, possessing abundant dendritic projections as shown in Fig. 1B . With transmission electron microscopy (Fig. 1C) , these cells showed fine needle-like dendrites in the cellular periphery and dense granules resembling periodic microstructures, which Ibisch et al. [9] reported to be an ultrastructural marker for canine DC, within the cytoplasm.
The flow cytometric analysis of these cells at 10 days of culture (Fig. 2) revealed strong expression of MHC class II on their surface, and expression of CD11c, a surface marker for DC, was also detected on almost all cells. These morphological and phenotypical features revealed that bone marrow cells cultured with recombinant feline GM-CSF and canine IL-4 differentiate into DC.
The yields of bone marrow-derived DC from five different dogs are shown in Table 1 . Bone marrow (0.3 to 0.7 ml) was aspirated from the dogs and the aspirate produced 1.6-9.2 × 10 6 of cells, predominantly DC, after 10 days of culture in the presence of GM-CSF and IL-4. The yield of the cells per ml of aspirate varied from 3 × 10 6 to 1.5 × 10 7 .
Functional characterization of bone marrow-derived dendritic cells:
To evaluate the functional properties of the bone marrow-derived DC, we examined their ability to phagocytose macromolecules, process pinocytosed soluble proteins, and activate allogeneic T cells. The ability of phagocytosis was confirmed by fluorescence-labeled latex microbeads incorporation by DC. Under the fluorescent microscope, DC were observed to phagocytose latex beads within 24 hr of incubation (Fig. 3A) . We examined the processing of pinocytosed soluble proteins with DQ-ovalbumin, a self-quenching ovalbumin that expresses fluorescence upon digestion, using flow cytometry. The DC incubated with DQ-ovalbumin at 37°C expressed fluorescence signals, while DC incubated at 4°C (as a control) did not exhibit fluorescence (Fig. 3B) , indicating that the bone marrow-derived DC possess the ability to pinocytose and process soluble proteins. We next performed an allogeneic T cell activation assay to evaluate the ability of bone marrow-derived DC to stimulate T cell proliferation compared with the ability of macrophages (Fig. 3C) . The proliferation rate, indicated by BrdU uptake, increased with an increasing number of DC to a constant number of allogeneic T cells (1 × 10 5 ) and it culminated with 3 × 10 4 of DC. The proliferation rate of T cells was higher with DC than with macrophages, especially at a DC cell number of 3 × 10 4 . Because the up-regulated expression of MHC class II and co-stimulatory molecules by activated DC is indispensable for ensuring that T cells will differentiate into effector cells [4, 13] , we examined the expressional changes of MHC class II, B7-1, and B7-2 by activation of bone marrowderived DC with lipopolysaccharide. The expressional changes of MHC class II were evaluated by flow cytometric analysis using specific antibody, and expressional changes of co-stimulatory molecules B7-1 and B7-2 were examined by mRNA expression using reverse transcription-polymerase chain reaction because specific antibodies for canine B7-1 and B7-2 were not available. At a dose of 250 ng/ml, lipopolysaccharide enhanced fluorescence intensity for MHC class II by DC (Fig. 4A ) and up-regulated both B7-1 and B7-2 mRNA expressions by DC (Fig. 4B) , suggesting that the bone marrow-derived DC have the potential to induce effector T cells by efficient antigen presentation. 
DISCUSSION
In the present report, we generated 1-9 × 10 6 DC from approximately 0.5 ml volume of canine bone marrow aspirate. Actually, the cells we generated from bone marrow using recombinant feline GM-CSF and canine IL-4 showed features shared with mouse and human DC (resident and generated) [10, 16, 18] : dendrite morphology and expression of cell surface molecules. Moreover, the DC demonstrated phagocytic activity for latex beads, processing activity of pinocytosed proteins examined by DQ-ovalbumin, and activation of allogeneic T cells that was far more potent than that of macrophages, indicating that the bone marrow-derived DC are fully functional for the capturing and processing of antigens and the initiation of T cell responses.
Although two previous reports had shown the generation of functional canine DC from bone marrow cells, their protocols required complicated procedures that included immunomagnetic beads selection of DC precursors; one required purification of lineage-negative cells by depletion of granulocytes, monocytes, and mature T and B cells [23] and the other required positive purification of CD34 + cells [8] . More recently, Gyorffy et al. [7] reported the successful generation of DC from canine bone marrow mononuclear cells without immunomagnetic beads selection. They generated DC using recombinant human cytokines (GM-CSF, TNF-α, Stem cell factor, and Flt3 ligand) and showed successful therapeutic application in cases of malignant melanoma, which is the only report attempting DC vaccination in clinical cases in dogs. However, they used 50 ml of bone marrow aspirate to generate a sufficient number of DC for vaccination (they used a minimum of 3-5 × 10 6 cells per dog).
For generation of bone marrow-derived DC, we used a combination of recombinant feline GM-CSF and canine IL-4. Feline GM-CSF shows a higher homology to canine GM-CSF (75% of identity) than that of human GM-CSF (70%), and IL-4 has been demonstrated to induce phenotypic maturation of DC [25] . Thus, the higher yield of the DC in our experiment is most likely due to the higher cross-reactivity of feline GM-CSF in addition to the use of IL-4.
In contrast to the generation of DC from bone marrow cells, to avoid the technical difficulty of bone marrow aspiration, Ibisch et al. [9] successfully established a method for the generation of DC from adherent peripheral blood mononuclear cells using recombinant canine GM-CSF, which is currently available as a commercial product from R&D Systems, and recombinant canine IL-4. They showed that these DC possessed the morphology and surface markers that are typical of DC in other species and demonstrated the ability to activate T cells. As mentioned in their discussion, the yield of DC (0.5-2 × 10 6 cells/20 ml of blood) is enough for the investigation of functional analysis but it is still low for therapeutic application. Although our method requires aspiration of bone marrow, the high yield presented in this report led us to consider that this approach is feasible for therapeutic vaccination. Our findings lay the foundation for the use of bone marrow-derived DC in vaccination against pathogens as well as malignant tumors in dogs.
